Pink Sheet Podcast: Medicare Price Negotiation List Preview, Mifepristone Ruling, AZ Sales Aid Warning Letter
Executive Summary
Pink Sheet reporters and editor discuss a projected list of drugs that could be eligible for the first round of Medicare price negotiations, the future of mifepristone access after the latest court decision, and AstraZeneca receiving the first US FDA drug promotion warning letter in more than a year.
You may also be interested in...
Preparing For A Shutdown: US FDA To Retain 81% Of Workforce, Thanks Mostly To User Fees
However, user fee carryover balances will not last forever and service cuts are inevitable if a shutdown lingers for several weeks.
Republican Lawmaker Takes Unusual Step Of Attacking FDA Salaries Over Abortion Pill Decisions
A move to cut senior FDA positions including CDER Director through the appropriations process is rare and almost certain to fail, but experts say the attempt is indicative of an environment that seems to be encouraging these personal amendments.
Intarcia’s Implantable GLP-1 Gets Unanimous No Vote But Lots Of New Trial Design Advice
A US FDA advisory panel feels there could be a place for Intarcia’s exenatide drug-device combo – if the company is willing to put in the work.